Tier 2 — strong

Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study

Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ

Nephrology Dialysis Transplantation 1999 14(6):1475-1479

Bibliography

PubMed: PMID 10383011
DOI: 10.1093/ndt/14.6.1475
Funding: Funding information is not available in the PubMed record reviewed for this entry.
Competing interests: Competing-interest information is not reported in the PubMed record reviewed for this entry.

Design	Randomized open crossover clinical trial.
Model	Adults on maintenance hemodialysis.
Sample	28 patients.
Intervention	Calcium ketoglutarate versus calcium acetate at equimolar elemental-calcium doses.
Duration	Two 12-week treatment periods separated by washout.
Endpoints	Serum phosphate; Hypercalcemia; PTH; Bicarbonate; Albumin; Calcitriol

This randomized crossover trial compared calcium ketoglutarate with calcium acetate in 28 maintenance-hemodialysis patients.

Both treatments lowered phosphate, while hypercalcemia occurred less often during the calcium-ketoglutarate arm in this study.

This contributes controlled human exposure data but addresses phosphate binding in kidney disease, not healthy-aging outcomes.

Calcium ketoglutarate significantly lowered serum phosphate.
Phosphate control was similar to calcium acetate.
Hypercalcemia was less frequent with calcium ketoglutarate than with calcium acetate in this cohort.

Open-label dialysis study, not a longevity trial.
The clinical context strongly affects calcium and phosphate outcomes.
Equimolar calcium dosing does not correspond to common retail Ca-AKG supplement use.

Citation network

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Last verified 20 September 2026